Format

Send to

Choose Destination
See comment in PubMed Commons below
Presse Med. 2011 Nov;40(11):1037-42. doi: 10.1016/j.lpm.2011.04.021. Epub 2011 Oct 5.

[Nephroprotection, fact or fiction?].

[Article in French]

Author information

1
Hôpitaux universitaires de Strasbourg, service de néphrologie, 67792 Strasbourg cedex, France. thierry.krummel@chru-strasbourg.fr

Abstract

Clinical studies of the last 15 years have shown the benefit of pharmacological interventions on the progression of chronic kidney disease, confirming the concept of nephroprotection. Pharmacological blockade of the renin angiotensin system remains the cornerstone of the nephroprotective treatment but the benefits and limitations are now better defined. The RAS blockers are all the more efficient than the proteinuria is abundant and nephroprotection is obtained in proportion to the reduction in proteinuria. Combinations of ACEI+ARA are not validated and their use should be considered only under the supervision of a specialist when optimal monotherapy has failed. The target blood pressure has been the subject of recent controversies, particularly in type 2 diabetic patients with nephropathy. The target should be individualized based on the main risk, renal or cardiovascular. Recent maneuvers have also shown a nephroprotective effect, including the correction of metabolic acidosis with sodium bicarbonate.

PMID:
21981881
DOI:
10.1016/j.lpm.2011.04.021
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center